Accretion/Dilution Analysis: Is This M&A Deal EPS Accretive?

Published: March 30, 2026

Article by Ryan O'Connell, CFA, FRM

When a public company announces an acquisition, one of the first questions from Wall Street analysts is: “Is this deal accretive or dilutive?” Accretion/dilution analysis is the methodology investment bankers use to answer that question — measuring whether an M&A transaction will increase or decrease the acquirer’s earnings per share. This analysis shapes how much a buyer can afford to pay and often determines whether a deal moves forward at all.

This guide covers how accretion/dilution analysis works, how to build the pro forma model step-by-step, the role of financing mix and synergies, break-even analysis, and why EPS impact is not the same as value creation.

What Is Accretion/Dilution Analysis?

Accretion/dilution analysis compares an acquirer’s pro forma EPS (after the transaction) to its standalone EPS (before the transaction). If pro forma EPS is higher, the deal is said to be accretive. If pro forma EPS is lower, the deal is dilutive.

This analysis is primarily relevant for public company acquirers because their stock prices are influenced by EPS expectations. Private equity buyers and other private acquirers use different metrics (IRR, cash-on-cash returns) since they don’t have publicly traded shares to dilute.

Public companies are often reluctant to pursue dilutive transactions because of the potential negative impact on their share price. Equity analysts forecast EPS, and missing those forecasts — even due to a strategically sound acquisition — can trigger a sell-off. For this reason, a buyer’s perception of valuation and corresponding bid price is often guided by accretion/dilution analysis. For more on M&A deal structuring, see our guide to mergers and acquisitions valuation.

Why EPS Matters in M&A

Earnings per share is one of the most closely watched metrics for public companies. It drives analyst coverage, investor sentiment, and often executive compensation. When a company announces an acquisition, the market immediately asks whether the deal will help or hurt EPS.

Analyst scrutiny: Sell-side analysts publish EPS estimates and track actual results against consensus. A dilutive acquisition can cause analysts to lower their EPS forecasts, which may pressure the stock price.

Management incentives: Executive compensation is frequently tied to EPS targets. This creates a natural bias toward accretive deals, even when a dilutive deal might create more long-term value.

Short-term vs long-term tension: Accretion/dilution analysis typically focuses on Year 1 (and sometimes Year 2-3) EPS impact. A deal that is dilutive in Year 1 but creates substantial value over five years may still face market resistance in the short term.

Step-by-Step: Building the Accretion/Dilution Model

The accretion/dilution model calculates pro forma combined EPS and compares it to the acquirer’s standalone EPS. The methodology below uses an EBT (earnings before taxes) bridge for consistency — all adjustments are made on a pre-tax basis, and taxes are applied once at the end.

Step 1: Determine the Purchase Price and Financing Structure

Start with the equity purchase price (what shareholders receive) and determine how it will be funded:

• Stock consideration: New acquirer shares issued to target shareholders
• Cash consideration: Funded by existing cash on hand or new debt
• Mixed consideration: A combination of stock and cash (most common)

For example, if the equity purchase price is $10 billion with 50% stock and 50% cash, the acquirer will issue $5 billion in stock and raise $5 billion in debt (or use balance sheet cash).

Step 2: Calculate New Shares Issued and Incremental Debt

For the stock portion:

• New Shares Issued = (Purchase Price × % Stock) ÷ Acquirer Share Price

For the cash portion (if debt-financed):

• New Debt = Purchase Price × % Cash

Step 3: Combine the Earnings (EBT Bridge)

Build the pro forma combined earnings before taxes:

Step 4: Calculate Incremental Interest Expense

For debt-financed acquisitions:

• Incremental Interest = New Debt × Cost of Debt

If using balance sheet cash instead of debt, consider the foregone interest income on that cash as an implicit cost.

Step 5: Calculate Pro Forma EPS and Compare

Advanced Nuance: Purchase-Accounting Adjustments

Real merger models include additional adjustments beyond the simplified framework above:

• Purchase price allocation (PPA): Writing up intangible assets creates incremental amortization expense that reduces pro forma earnings
• Financing fee amortization: Debt issuance costs are amortized over the loan term
• Target debt refinancing: If target debt is repaid or refinanced at close, the interest expense changes
• Transaction costs: Advisory fees, legal costs, and integration expenses (often excluded from “core” accretion/dilution)

These adjustments can materially affect the accretion/dilution outcome. For this article, we focus on the core mechanics; in practice, bankers build sensitivity tables around these assumptions.

The Role of the Acquisition Multiple and Financing Mix

Two factors drive whether a deal is accretive or dilutive: the price paid (reflected in the acquisition multiple) and the financing structure.

Acquisition Multiple Impact

The higher the multiple paid for the target, the more dilutive the deal becomes. Paying 20× earnings for a target is more dilutive than paying 12× for the same earnings stream — you’re giving up more (shares or interest expense) for the same earnings contribution.

Stock Deals

In an all-stock deal, the acquirer issues new shares to target shareholders. This dilutes existing shareholders’ ownership. The deal is accretive only if the acquirer’s P/E ratio is higher than the implied offer P/E (the P/E multiple being paid for the target).

Cash Deals (Debt-Financed)

In a debt-financed cash deal, the acquirer takes on interest expense instead of issuing shares. The deal is accretive if the target’s earnings yield at the offer price exceeds the acquirer’s after-tax cost of debt.

Mixed Financing

Most deals use a combination of stock and cash to balance the trade-offs. The optimal mix depends on the acquirer’s cost of capital, balance sheet capacity, and target shareholders’ preferences.

When Does a Deal Accrete? The Break-Even Analysis

Break-even analysis determines the maximum price (or minimum synergies) at which a deal remains accretive. This helps acquirers set bid limits and negotiate effectively.

Break-Even Offer P/E (Stock Deals)

For an all-stock deal with no synergies, the break-even occurs when:

If the acquirer trades at 20× earnings, it can pay up to 20× for the target (including any premium) before the deal becomes dilutive on a standalone basis.

Break-Even Earnings Yield (Cash Deals)

For a debt-financed cash deal:

If the acquirer’s after-tax cost of debt is 4%, and the target’s earnings yield at the offer price is 6%, the deal is accretive. If the target’s earnings yield is only 3%, it’s dilutive.

Synergies and Their Effect on Accretion

Synergies provide a “cushion” that can turn a dilutive deal accretive. They increase pro forma combined earnings, offsetting the financing cost of the acquisition.

Types of Synergies

• Cost synergies: Headcount reductions, facility consolidation, procurement savings, elimination of redundant overhead. These are more predictable and typically realized within 1-3 years.
• Revenue synergies: Cross-selling, market expansion, pricing power. These are harder to achieve and often discounted or excluded from accretion/dilution analysis.

Break-Even Synergies

The break-even synergies calculation shows the minimum synergies required to make a deal accretive:

From the Rosenbaum & Pearl example: if a deal shows a $0.18 per-share shortfall (dilution) with 125 million pro forma shares and a 38% tax rate, break-even synergies = ($0.18 × 125M) ÷ (1 − 0.38) = $36.3 million pre-tax.

Cost of Financing vs Target Earnings Yield

At its core, accretion/dilution is about yield arbitrage. The acquirer is “paying” for the target’s earnings stream with either equity (at its own earnings yield) or debt (at its borrowing cost). If the target’s earnings yield at the offer price exceeds the financing cost, the deal is accretive.

Stock Deal Intuition

When issuing stock, the acquirer is effectively “selling” its own earnings at its P/E multiple to “buy” the target’s earnings at the offer P/E. If the acquirer’s P/E is 20× (5% earnings yield) and it pays 15× for the target (6.7% earnings yield), the deal is accretive — the acquirer is exchanging lower-yielding currency for higher-yielding earnings.

Debt Deal Intuition

When using debt, the acquirer borrows at its cost of debt to capture the target’s earnings yield. If borrowing costs 5% after-tax and the target yields 8% at the offer price, the spread is positive and the deal accretes.

This explains why high-P/E acquirers often prefer stock deals — their “currency” is expensive (low earnings yield), making it easier to acquire lower-P/E targets accretively.

Accretion/Dilution vs NPV Analysis

Accretion/dilution analysis and NPV analysis answer fundamentally different questions. Understanding this distinction is critical for sound M&A decision-making.

Key insight: A deal can be NPV-positive (creates shareholder value) but EPS-dilutive, or NPV-negative (destroys value) but EPS-accretive. For example, acquiring a high-growth company at a premium may be dilutive in Year 1 but create substantial long-term value. Conversely, buying a slow-growth company cheaply may be immediately accretive but destroy value if the target declines.

Sophisticated acquirers use both frameworks: accretion/dilution for market communication and NPV for internal decision-making. For more on NPV methodology, see our guide to net present value and IRR.

Limitations of EPS-Focused M&A Analysis

While widely used, accretion/dilution analysis has significant limitations that every practitioner should understand.

1. Ignores time value of money. A deal that’s dilutive in Year 1 but creates value over 10 years may be rejected due to short-term focus.

2. Doesn’t capture strategic rationale. Market position, technology acquisition, talent, and competitive dynamics are not reflected in EPS math.

3. Can be manipulated. Financing structure, accounting choices, and synergy assumptions can all be adjusted to show a more favorable outcome.

4. Quality of earnings issues. GAAP EPS may not reflect economic reality due to non-cash items, one-time charges, or aggressive revenue recognition.

5. Short-term focus may destroy long-term value. Pressure to be accretive can cause management to avoid strategically sound but dilutive deals, or to overpay for slow-growth targets that appear “cheap.”

Common Mistakes

Even experienced analysts make errors when performing accretion/dilution analysis. Here are the most common pitfalls:

1. Ignoring diluted share count. Using basic shares instead of fully diluted shares (Treasury Stock Method) understates the dilutive impact of stock-based compensation, options, and convertibles.

2. Mixing EPS definitions inconsistently. Using GAAP EPS for one company and adjusted EPS for another makes the comparison meaningless. Normalize both to the same basis — typically adjusted EPS excluding one-time items.

3. Treating synergies as guaranteed. Synergies are estimates, not certainties. Always build sensitivity analysis showing outcomes at 50%, 75%, and 100% synergy realization.

4. Ignoring financing costs for “cash” deals. Even if cash is on the balance sheet, using it has an opportunity cost — the foregone interest income or alternative investment returns.

5. Focusing on Day 1 accretion only. A deal may be dilutive in Year 1 but accretive by Year 2-3 as synergies ramp. Multi-year trajectory matters.

6. Confusing EPS accretion with value creation. An accretive deal is not necessarily a good deal. If you overpay, you can still destroy shareholder value even while showing EPS accretion.

7. Comparing to the target’s unaffected trading P/E. The relevant comparison is to the offer P/E (including any premium), not the target’s pre-announcement trading multiple.

How to Calculate Accretion/Dilution

To summarize the process:

1. Determine purchase price and financing mix (stock vs cash)
2. Calculate new shares issued and/or incremental debt
3. Build pro forma combined EBT (acquirer + target + synergies − incremental interest)
4. Apply tax rate to get pro forma net income
5. Divide by pro forma diluted shares to get pro forma EPS
6. Compare to acquirer standalone EPS